Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03023878 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03023878 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 47 participants.
The verdict
NCT03023878, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
Interventions
- DRUG Dexamethasone
- DRUG Blinatumomab
- DRUG Investigator's Choice Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03023878
The ClinicalTrials.gov registry entry for NCT03023878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03023878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03023878 about?
NCT03023878 is a clinical study titled "Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma". A phase 2, multicenter, open-label, single arm clinical trial in adults with newly diagnosed aggressive high-risk DLBCL.
What is the current status of trial NCT03023878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-03-13. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03023878?
The interventions under investigation include: Dexamethasone (DRUG), Blinatumomab (DRUG), Investigator's Choice Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03023878?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.